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Summary 
Atypical teratoid/rhabdoid tumor (AT/RT) is a rhabdoid tumor of the central nervous 
system comprising a mixture of small round cells and mesenchymal and/or epithelial elements, 
showing mutation of the SMARCB1 gene or SMARCA4 gene. The epidermal growth factor receptor 
(EGFR) is one of the tyrosine kinase receptors whose overexpressed protein plays important roles in 
the malignant characteristics of various tumors. We analyzed 8 Japanese cases of AT/RT for EGFR 
protein overexpression and egfr gene amplification using immunohistochemistry and fluorescence in 
situ hybridization. The patients included 7 boys and one girl (age range 13 days – 2 years), and the 
tumors were localized in the frontal lobe (1 case), lateral ventricle (1 case), third ventricle (1 case), 
fourth ventricle (3 cases), and cerebellum (2 cases). We found that all (100%) of them partially 
expressed a high level of EGFR protein, and that one case showed amplification of egfr, the 
amplified area being localized and limited to a specific area within the tumor. We speculate that 
AT/RT is a tumor with heterogeneous egfr amplification, and that the frequency of amplification 
may depend on loss of function of the specific chromatin-remodeling member. 
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Introduction 
Rhabdoid tumor was originally described in 1978 as a primary malignant 
“rhabdomyosarcomatous variant” of Wilms’ tumor in the kidney [1]. In 1996, Rorke et al. first 
proposed a distinct entity: atypical teratoid/rhabdoid tumor (AT/RT) of the brain, comprising a 
mixture of rhabdoid tumor, a tumor with small round cells, and mesenchymal and/or epithelial 
elements [2]. Biegel et al. subsequently reported monosomy 22 or deletion of chromosome 22q11 as 
the primary cytogenetic change in AT/RT, and found that SMARCB1(hSNF5/INI-1) mutation was 
included in the affected region. Subsequently, SMARCB1 mutation was also detected in cases of 
AT/RT without chromosomal abnormality of chromosome 22q11 [3, 4]. More recently, cases of 
AT/RT without SMARCB1 mutation have also been reported. These tumors retained SMARCB1 
expression but had mutation of SMARCA4, which is another member of the SWI/SNF 
chromatin-remodeling complex [5]. Clinicopathologically, AT/RT of the central nervous system is 
an extremely aggressive tumor of early childhood. The current estimated incidence of AT/RT is 
2–3% of all primary CNS tumors in children. When aggressive multidisciplinary therapies are 
adopted, the median survival period is 16.75 months and the median event-free survival is 10 months 
[6]. 
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The epidermal growth factor receptor (EGFR) is one of the tyrosine kinase receptors, and 
overexpressed EGFR protein plays important roles in the malignant characteristics of various tumors. 
Among brain tumors, EGFR protein overexpression is detected in glioblastoma, and is usually 
associated with egfr amplification [7].  
There have been conflicting reports concerning the status of EGFR protein expression 
and egfr amplification in AT/RT. Jeibmann et al. found neither egfr amplification nor EGFR 
overexpression in 9 cases of AT/RT [8], whereas Patereli et al. found that among 7 such cases, 3 
were positive for EGFR expression [9].  
In the present study, we investigated the EGFR status of AT/RT using 
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) with serial 
formalin-fixed, paraffin-embedded sections of surgical specimens.  
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Materials and Methods 
Cases 
We analyzed 8 Japanese cases of AT/RT. The affected patients included 7 boys and one 
girl (age range 13 days – 2 years), and the tumors were localized in the frontal lobe (1 case), lateral 
ventricle (1 case), third ventricle (1 case), fourth ventricle (3 cases), and cerebellum (2 cases) (Table 
1).  
 
Immunohistochemistry 
For immunohistochemical analysis, the following antibodies (clone) and their dilutions 
were used as primary antibodies: anti-EGFR (clone : 2-18C9, Dako Japan, Tokyo, Japan) 1:50, 
anti-EMA (E29, mouse monoclonal, Dako Japan) 1:100, anti-GFAP (rabbit polyclonal, Dako Japan) 
1:100, anti-p53 (DO-7, mouse monoclonal, Dako Japan) 1:100, anti-synaptophysin (SY38, mouse 
monoclonal, Dako Japan) 1:50, anti-vimentin (V9, mouse monoclonal, Dako Japan) 1:200, 
anti-S-100 protein (rabbit polyclonal, Dako Japan) 1:500, anti-SMA (1A4, mouse monoclonal, Dako 
Japan) 1:200, anti-BAF47/INI-1 (25/BAF47, mouse monoclonal, BD, Nippon Becton Dickinson, 
Tokyo, Japan) 1:50, anti-Ki-67 (MIB-1, mouse monoclonal, Dako Japan), 1:100, anti-desmin (D33, 
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mouse monoclonal, Dako Japan), and anti-pankeratin (AE1/AE3 and PCK26, cocktail antibody, 
Ventana, Roche Tissue Diagnostics Japan, Tokyo, Japan). 
All of the specimens had been previously fixed in 15% formalin and embedded in 
paraffin. Serial sections were cut at a thickness of 2 µm, placed on slides, then deparaffinized in 
xylene and rehydrated in an ethanol series. The specimens were incubated with ChemMate POD 
Blocking Solution (Dako Japan) for 5 min at room temperature. After blocking, the sections were 
incubated with each primary antibody diluted in Dako REAL Antibody Diluent (Dako Japan) for 30 
min at room temparature. Heat-mediated antigen retrieval was performed as follows: autoclaving for 
15 min at 105℃: anti-EGFR, anti-p53, anti-synaptophysin, and anti-BAF47/INI-1; autoclaving for 
10 min at 120℃: anti-GFAP, anti-vimentin, anti-SMA, anti-desmin, and anti-Ki-67. No antigen 
retrieval was performed for anti-EMA and anti-S-100 protein. The specimens were washed in Dako 
Wash Buffer and the EnVision® (Dako Japan) signal enhancement system was employed. These 
immunohistochemical processes were performed with histostainer (Nichirei Biosciences Inc., Tokyo, 
Japan) and the Ventana NexES® IHC staining system (Ventana, Roche Tissue Diagnostics Japan). 
EGFR expression was scored in terms of intensity and the proportion of positive cells.  
The stained specimens were evaluated by light microscopy, using a x10 objective. Only clear 
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staining of the tumor cell membranes was considered positive. Diffuse cytoplasmic or granular 
staining was diagnosed as negative. A semi-quantitative approach was used to generate a score for 
each tissue slide, as follows. The percentage of positive tumor cells was scored at intervals of 10% 
(0% to 100%). The dominant intensity pattern of staining was scored as: 1, negative or trace; 2, 
weak; 3, moderate; or 4, intense (Fig.1 A-D). The total score was calculated by multiplying the 
intensity score and the fraction score, producing a total range of 0–400. Specimens with low levels 
of expression were re-evaluated for the presence or absence of membranous or cytoplasmic staining 
using a x40 objective. Immunohistochemistry assays were evaluated by two independent 
pathologists (KS and YMo) who were blinded to the clinical data and the results of fluorescence in 
situ hybridization (FISH) to determine gene amplification, as described below. A consensus was 
reached for each slide after discussion of the results [10]. 
 
Fluorescence in situ hybridization (FISH) 
Dual-color, dual-target FISH assays were performed using the LSITM EGFR Spectrum 
Orange/CEP7 Spectrum Green Probe (Vysis, Abbott Japan, Tokyo, Japan). 
4'6-Diamidino-2-phenylindole (DAPI) (DAPI I, Vysis, Abbott Japan) was used for chromatin 
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counterstaining. All specimens had been previously fixed in 15% formalin and embedded in paraffin. 
Sections 5 µm thick were deparafﬁnized, rehydrated, and immersed in 0.2 N HCl for 10 min, then 
incubated in pretreatment solution (Vysis, Abbott Japan) for 30 min at 80℃, and digested with 
protease solution for 30 min at room temperature. The sections were incubated in probe solution 
(Vysis, Abbott Japan) at 73℃ for 5 min to co-denature the EGFR and CEP7 probes, and left 
overnight to hybridize at 37℃. Post-hybridization stringency washing was done in a water bath at 
72℃ for 4 min. After washing and wiping off the wash buffer, the sections were stained with DAPI 
(Vysis, Abbott Japan) and then mounted under coverslips. 
 Analyses were performed using a ﬂuorescence microscope (BZ-9000, Keyence Corp., Osaka, 
Japan). The EGFR gene was visualised as a red signal using a Spectrum Orange ﬁlter, CEP7 as a 
green signal using a ﬂuorescein isothiocyanate ﬁlter, and nuclei as a blue signal using a DAPI ﬁlter. 
Two independent pathologists (KS and YMo) scored at least 100 non-overlapping interphase nuclei 
for the number of copies of EGFR and CEP7, and then a consensus about each slide was reached 
after discussion. The observers were blinded to the clinical data and the results of 
immunohistochemistry. EGFR status was scored as the number of EGFR signals per nucleus and as 
the ratio of EGFR signals to CEP7 signals. Negative controls consisted of non-tumoral colorectal 
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mucosa contiguous with adenocarcinoma, which was the positive control for ampliﬁed EGFR. An 
increased EGFR copy number was deﬁned as the presence of three or more signals per nucleus. 
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Results 
We analyzed 8 Japanese cases of AT/RT for EGFR protein overexpression and egfr gene 
amplification. These 8 cases were diagnosed as AT/RT according to the WHO Classification of 
Tumours of the Central Nervous System, fourth edition [11]. The 8 affected patients included seven 
boys and one girl (age range 13 days – 2 years), and the tumors were localized in the frontal lobe (1 
case), lateral ventricle (1 case), third ventricle (1 case), fourth ventricle (3 cases), and cerebellum (2 
cases) (Table 1). Although the sample set was small, the marked male predilection was noteworthy. 
There was no other evident trend in the patient profiles. 
All 8 cases showed diagnostic morphological features such as rhabdoid cells and 
embracing cells (Fig.2 A-C). In addition, various phenotypes were confirmed using 
immunohistochemistry (data not shown). The tumors always focally expressed GFAP, 
synaptophysin, S-100 protein, SMA, cytokeratin (pankeratin), EMA, and vimentin. All of these 
cases were negative for desmin. Most of the tumor cells were positive for p53 in every case. 
Furthermore, all showed loss of nuclear expression of BAF47/INI1 in the tumor cells, whereas 
positive expression was confirmed in capillary endothelia as an internal control (Fig.2D).  
All 8 cases (100%) expressed the EGFR protein (Table 1, Fig.3). The EGFR-positive 
Satomi. et. al.12 
 
areas showed not only a diffuse pattern but also single-cell positivity. There were no correlations 
between the immunohistochemical scores and clinical features, or between EGFR-positive cells and 
any specific histological features. EGFR expression showed no association among histological 
features such as rhabdoid cells, embracing cells, epithelioid cells, spindle cells, papillary structures, 
adenomatous areas, or poorly differentiated ribbons and cords (data not shown). 
Fluorescence in situ hybridization (FISH) analysis was performed to detect egfr 
amplification. Surprisingly, one case (case No.3 in Table 1, 1/8, 12.5%) showed focal egfr 
amplification (Table 1, Fig.4 A,B). The other seven cases showed no amplification in any of the 
microscopic fields examined. Case No.3, with an area of egfr amplification, showed relatively higher 
semi-quantitative immunohistochemical scores (Proportion: 40, Intensity: 4, Score: 160), but these 
were not the highest scores among the 8 cases. To clarify the association between the area of egfr 
amplification and the area of EGFR protein expression, we reviewed serial sections of FISH 
specimens using immunohistochemistry. The serial area of amplification showed strong 
heterogeneous EGFR positivity (intensity=4) and it extended to 40% of the specimen (Proportion 
=40) (Fig.4 C,D). 
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Discussion 
The aim of this study was to assess EGFR protein overexpression and the frequency of 
egfr gene amplification in cases of AT/RT [8, 9]. We detected EGFR protein expression in all 8 
cases of AT/RT examined, and one case showed egfr amplification. Interestingly, the area of egfr 
amplification was localized and limited in extent. 
On the basis of our results, it seemed that EGFR expression and egfr amplification were 
not associated with each other, or with any cell type, despite intensive examination of many 
microscopic fields. However, the amount of specimens was admittedly small, and the clones of the 
antibodies or FISH probes used may have been responsible for the discrepancy between our results 
and those of previous studies. 
Various solid tumors show high levels of EGFR protein overexpression. Since the EGFR 
is a tyrosine kinase receptor, its high expression is associated with oncogenesis or tumor progression. 
Anti-EGFR molecular targeted therapy is now widely accepted for patients with colon cancers. 
Amplification of egfr leads to overexpression of EGFR protein [13], and this is associated with poor 
prognosis; egfr amplification is also predictive of the efficacy of anti-EGFR agents in patients with 
colon cancer [14]. In breast cancer, however, amplification of egfr and overexpression of EGFR 
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protein are not always correlated. This may be due to epigenetic regulation, and microsatellite 
alterations in the regulating sequences of egfr have already been reported [15, 16]. 
Recently, Singh et al. reported that inhibition of the EGFR-ErbB2 signal pathway with 
lapatinib resulted in antitumor activity in AT/RT cell lines [12]. Although there are currently no 
clinical data for the use of lapatinib in AT/RT, this report showed that human AT/RT tumor cells are 
dependent on the EGFR-ErbB2 signal pathway, and that it would be a potentially useful therapeutic 
target in AT/RT. Since INI1/hSNF5, SMARCB1, and SMARCA4 are core members of the 
adenosine triphosphate (ATP)-dependent SWI/SNF chromatin-remodeling complex, genetic 
alteration in any of them leads to chromatin instability. This may result in non-homogeneous or 
unusual egfr amplification in a tumor. Therefore, we speculate that AT/RT is a tumor with 
heterogeneous egfr amplification, and that the frequency of amplification may depend on the loss of 
function of the specific chromatin-remodeling member. Aberration of the chromatin modifier is also 
able to explain how EGFR expression and egfr amplification differ according to tumor area or 
among cells. That is, the egfr gene is thought not to be stabilized in individual tumor cells, and its 
level of amplification may thus differ, even within a small area (Fig.4A). Our immunohistochemical 
analysis of serial sections from case No.3 showed that EGFR-positive cells were not distributed 
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uniformly within a given area, thus supporting the above possibility. 
In recent years, the Notch and EGFR pathways have been shown to regulate neural stem 
cells and neural progenitor cells [17]. The type of cell from which AT/RT originates is still under 
debate, and possible candidates include meningeal cells and germ cells. However, neural stem cells 
and neural progenitor cells have also been suggested, and it is possible that EGFR-positive cells 
interact with the Notch pathway and regulate neural stem/progenitor-like cells, thus acting as “tumor 
initiating cells”. The Notch-EGFR pathway or its member molecules may thus be promising new 
candidates for molecular targeted therapy. 
Our present results support the possibility that AT/RT is a multi-phenotypic tumor with 
aberration of the chromatin modifier, and we speculate that it is an embryonal tumor in which neural 
stem cells or neural progenitor cells play an important role.  
 
 
 
 
 
Satomi. et. al.16 
 
Conﬂict of interest 
None of the authors have any potential conﬂicts of interest to declare. 
 
Acknowledgment 
We thank Junko Hirato MD, PhD, and Atsuko Nakazawa MD, PhD, for advice with pathological 
diagnosis. 
 
 
 
 
 
 
 
 
 
 
Satomi. et. al.17 
 
References 
[1] J.B. Beckwith, N.F. Palmer, Histopathology and prognosis of Wilms’ tumors: results from the 
First National Wilms’ Tumor Study, Cancer 41 (1978) 1937-1948. 
[2] L.B. Rorke, R.J. Packer, J.A. Biegel, Central nervous system atypical teratoid/rhabdoid tumors of 
infancy and childhood: definition of an entity, J. Neurosurg. 85 (1996) 56-65. 
[3] J.A. Biegel, L.B. Rorke, R.J. Packer, B.S. Emanuel, Monosomy 22 in rhabdoid or atypical 
tumors of the brain, J. Neurosurg. 73 (1990) 710-714. 
[4] J.A. Biegel, C.S. Allen, K. Kawasaki, N. Shimizu, M.L. Budarf, C.J. Bell, Narrowing the critical 
region for a rhabdoid tumor locus in 22q11, Genes Chromosomes Cancer 16 (1996) 94-105. 
[5] M. Hasselblatt, S. Gesk, F. Oyen, S. Rossi, E. Viscardi, F. Giangaspero, C. Giannini, A.R. 
Judkins, M.C. Fruhwald, T. Obser, R. Schneppenheim, R. Siebert, W. Paulus, Nonsense mutation 
and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained 
SMARCB1 (INI1) expression, Am. J. Surg. Pathol. 35 (2011) 933-935. 
[6] J.M. Hilden, S. Meerbaum, P. Burger, J. Finlay, A. Janss, B.W. Scheithauer, A.W. Walter, L.B. 
Rorke, J.A. Biegel, Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in 
children enrolled in a registry, J. Clin. Oncol. 22 (2004) 2877-2884. 
Satomi. et. al.18 
 
[7] L.J. Layfield, C. Willmore, S. Tripp, C. Jones, R.L. Jensen, Epidermal growth factor receptor 
gene amplification and protein expression in glioblastoma multiforme: prognostic significance and 
relationship to other prognostic factors, Appl. Immunohistochem. Mol. Morphol. 14 (2006) 91-96. 
[8] A. Jeibmann, H. Buerger, M. Fruhwald, M. Hasselblatt, No evidence for epidermal growth factor 
receptor amplification and overexpression in atypical teratoid/rhabdoid tumors, Acta Neuropathol. 
112 (2006) 513-514. 
[9] A. Patereli, G.A. Alexiou, K. Stefanaki, M. Moschovi, I. Doussis-Anagnostopoulou, N. 
Prodromou, O. Karentzou, Expression of epidermal growth factor receptor and HER-2 in pediatric 
embryonal brain tumors, Pediatr. Neurosurg. 46 (2010) 188-192. 
[10] F.R. Hirsch, M. Varella-Garcia, P.A. Bunn, Jr., M.V. Di Maria, R. Veve, R.M. Bremmes, A.E. 
Baron, C. Zeng, W.A. Franklin, Epidermal growth factor receptor in non-small-cell lung 
carcinomas: correlation between gene copy number and protein expression and impact on prognosis, 
J. Clin. Oncol. 21 (2003) 3798-3807. 
[11] David N. Louis, Hiroko Ohgaki, Otmar D. Wiestler, Webster K. Cavenee, WHO Classification 
of Tumours of the Central Nervous System, Fourth Edition, 2007, pp. 147-149. 
[12] A. Singh, X. Lun, A. Jayanthan, H. Obaid, Y. Ruan, D. Strother, S.N. Chi, A. Smith, P. Forsyth, 
Satomi. et. al.19 
 
A. Narendran, Profiling pathway-specific novel therapeutics in preclinical assessment for central 
nervous system atypical teratoid rhabdoid tumors (CNS ATRT): Favorable activity of targeting 
EGFR- ErbB2 signaling with lapatinib, Mol. Oncol. 7 (2013) 497-512. 
[13] A. Ooi, T. Takehana, X. Li, S. Suzuki, K. Kunitomo, H. Iino, H. Fujii, Y. Takeda, Y. Dobashi, 
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an 
immunohistochemical and fluorescent in situ hybridization study, Mod. Pathol. 17 (2004) 895-904. 
[14] M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-Bianchi, F. Di Nicolantonio, 
M. Gambacorta, S. Siena, A. Bardelli, Gene copy number for epidermal growth factor receptor 
(EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study, Lancet 
Oncol. 6 (2005) 279-286. 
[15] N. Tidow, A. Boecker, H. Schmidt, K. Agelopoulos, W. Boecker, H. Buerger, B. Brandt, 
Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early 
steps in breast cancer development, Cancer Res. 63 (2003) 1172-1178. 
[16] H. Buerger, F. Gebhardt, H. Schmidt, A. Beckmann, K. Hutmacher, R. Simon, R. Lelle, W. 
Boecker, B. Brandt, Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr 
is related to cytogenetic alterations and epithelial growth factor receptor expression, Cancer Res. 60 
Satomi. et. al.20 
 
(2000) 854-857. 
[17] A. Aguirre, M.E. Rubio, V. Gallo, Notch and EGFR pathway interaction regulates neural stem 
cell number and self-renewal, Nature 467 (2010) 323-327. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Satomi. et. al.21 
 
Figure Legends 
Fig.1 The intensity of immunohistochemical staining for EGFR. 
The intensity was graded as: 1, negative or trace (A); 2, weak (B); 3, moderate (C); or 4, intense (D). 
Scale bar is 50 µm. 
 
Fig.2 Histological features of atypical teratoid /rhabdoid tumors (AT/RTs). 
A: In a low-power field, AT/RTs may contain areas that mimic other embyronal tumors such as 
medulloblastoma or central nervous system primitive neuroectodermal tumor. The tumor is 
composed of highly cellular, densely packed small round cells. 
B: Rhabdoid cells are also a characteristic feature of AT/RTs. These cells have vesicular chromatin, 
prominent nucleoli and eosinophilic globular cytoplasmic inclusions. Ultrastructurally, whorls of 
intermediate filaments are evident. 
C: Embracing cells are another characteristic feature of AT/RTs. These cells are sickle-shaped and 
appear to embrace another tumor cell. 
D: Immunohistochemical staining for expression of the INI-1/BAF47 protein is the most sensitive 
and specific marker for AT/RTs. The expression of INI-1/BAF47 protein is lost in tumor nuclei, but 
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retained in the intratumoral endothelia. 
Scale bar is 100 µm in A and D, 10 µm in B and C. 
 
Fig.3 Immunohistochemical features of atypical teratoid /rhabdoid tumors. 
A: HE, B: Immunohistochemistry for EGFR. The EGFR-positive cells appear to be localized in 
islands of tumor cells with clear cytoplasm. However, some other scattered tumor cells localized 
outside the islands are also positive. 
Scale bar is 500 µm. 
 
Fig.4 Dual color FISH assays using probes for EGFR (red) and chromosome 7 (CEP7, green) and 
immunohistochemistry of serial sections (case No.3). 
A: Amplified area. Red signals represent amplification of the egfr gene (by more than 10-fold). 
Green signals represent the centromere of chromosome 7, which contains the egfr gene. 
B: Balanced disomic tumor cells. There is no egfr amplification. 
C: An area with egfr amplification in a serial section. EGFR-positive cells and negative cells are 
admixed, and positive cells show strong positivity. 
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D: An area without egfr amplification in a serial section. There are scattered EGFR-positive cells, 
but most of the tumor cells show no EGFR positivity. 
Scale bar is 10 µm. 
Table 1  Patient profiles, immunohistochemistry and gene amplification. 
 
 Patient profile Immunohistochemistry FISH 
 Case Age Sex Tumor locus* Proportion Intensity Score† (EGFR/CEP7) 
     (0-100) (1-4) (0-400)  
 1 2 y.o. M  Rt. LV 10 2 20 1.05 
 2 1 y.o. M  4th ventricle 30 4 120 0.97 
 3 2 y.o. F  3rd ventricle 40 4 160 >10‡ 
 4 1 y.o. M  4th ventricle 20 4 80 1.04 
 5 13 days M  cerebellum 30 3 90 1.10 
 6 2 y.o. M  4th ventricle 10 1 10 1.04 
 7 3 mo. M  cerebellum 30 4 120 1.43 
 8 1 y.o. M Rt. FL  70 4 280 1.14 
 
* LV: lateral ventricle, FL: frontal lobe 
† The score was calculated by multiplying the proportion and the intensity, producing a total range of 0-400. 
‡ Amplification 
A B 
C D 
Fig.1
A B 
C D 
Fig.2
A B 
Fig.3
A B 
C D 
Fig.4
